(NASDAQ: MRKR) Marker Therapeutics's forecast annual revenue growth rate of 184.27% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 119.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.3%.
Marker Therapeutics's revenue in 2026 is $4,694,989.On average, 5 Wall Street analysts forecast MRKR's revenue for 2026 to be $45,917,792, with the lowest MRKR revenue forecast at $0, and the highest MRKR revenue forecast at $101,539,343. On average, 5 Wall Street analysts forecast MRKR's revenue for 2027 to be $331,378,399, with the lowest MRKR revenue forecast at $42,483,128, and the highest MRKR revenue forecast at $575,222,882.
In 2028, MRKR is forecast to generate $2,093,644,557 in revenue, with the lowest revenue forecast at $1,634,366,601 and the highest revenue forecast at $2,559,491,726.